左西孟旦联合地高辛在扩张型心肌病心衰患者中的临床研究  

Clinical Effect of Combined Treatment with Levosimendan and Digoxin in Hear Failure Subjects with Dilated Cardiomyopathy

作　　者：陈文生[1] 李广平[2] 杨立明[1] 孙淑娴[1] 赵庆霞[1] 张宇[1] 邸亚丽[1] 纪征[1] 

机构地区：[1]唐山工人医院心内一科,唐山市063000 [2]唐山工人医院检验科,唐山市063000

出　　处：《中国分子心脏病学杂志》2016年第3期1695-1697,共3页Molecular Cardiology of China

摘　　要：目的探讨左西孟旦与地高辛联合治疗扩张型心肌病心力衰竭的临床疗效。方法将满足条件的我院2013年至2015年收治的116例扩张型心肌病心衰患者随机分为实验组(接受左西孟旦与地高辛联合用药)和对照组(地高辛常规用药),对两组患者治疗前后心功能分级指标、超声心动图和血浆氨基末端B型钠尿肽前体(NTpro-BNP)指标进行比较分析。结果治疗3周后,实验组总有效率显著高于对照组(94.83%vs 77.59%,P<0.05);实验组超声提示实验组左室射血分数LVEF显著高于对照组(45.56%vs41.76%,P<0.05),实验组每博量SV显著高于对照组(76.13ml vs 72.47ml,P<0.0001);实验组氨基末端B型钠尿肽前体(NT-proBNP)降低到平均485.54ng/L,优于对照组541.12ng/L(P<0.05)。结论左西孟旦与地高辛联合治疗扩张型心肌病心衰的疗效优于常规地高辛治疗。Objective To investigate the treatment effect with combined levosimendan and digoxin for heart failure subjects with dilated cardiomyopathy. Methods 116 subjects met criteria were enrolled and randomized into testing group （treatment with levosimendan and digoxin） and control group （treatment with Digoxin）. New York Heart Association （NYHA） Functional Classification, cchocardiography and whole blood N-terminal B type natriuretic peptide precursor （NT-proBNP） were reported to evaluate the clinical effect for these two groups. Results After 3 weeks treatment, the overall effective rate for testing group was significant higher than control group （94.83% vs 77.59%, P〈0.05）; Echocardiography results reported that testing group has significant difference with control group （LVEF, 45.56% vs 41.76%, P〈0.05; SV, 76.13ml vs 72.47ml, P〈0.0001）; The mean of NT-proBNP for testing group was 485.54ng/L while control group was 541.12ng/ L with P〈0.05. Conclusions Treatment with combined levosimendan and digoxin is superior than digoxin only for heart failure subjects with dilated cardiomyopathy.

关 键 词：左西孟旦 地高辛 扩张型心肌病 心力衰竭 

分 类 号：R542.2[医药卫生—心血管疾病]